Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis : A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP
Copyright © 2023 by The American College of Gastroenterology..
INTRODUCTION: For the treatment of spontaneous bacterial peritonitis (SBP), cefotaxime, ceftriaxone, and ciprofloxacin were used as first-line agents. However, considering the increasing rate of antibiotic resistance, it is unclear which of these drugs can be initially recommended. This study aimed to compare the current efficacy of the 3 antibiotics, namely cefotaxime, ceftriaxone, and ciprofloxacin, for the treatment of SBP in patients with cirrhosis with ascites, when guided by therapeutic responses.
METHODS: This study was a multicenter, prospective, randomized controlled trial. The inclusion criteria were 16- to 75-year-old patients with liver cirrhosis with ascites, having polymorphonuclear cell count of >250/mm 3 . We performed a follow-up paracentesis at 48 hours to decide continuing or changing the assigned antibiotics and then assessed the resolution rates at 120 and 168 hours of treatment.
RESULTS: A total of 261 patients with cirrhosis who developed SBP were enrolled. Most of the patients were diagnosed as those with SBP within 48 hours of admission. The resolution rates at 120 hours, which is the primary endpoint, were 67.8%, 77.0%, and 73.6% in the cefotaxime, ceftriaxone, and ciprofloxacin groups, respectively ( P = 0.388), by intension-to-treat analysis. The 1-month mortality was similar among the groups ( P = 0.770). The model for end-stage liver disease score and the SBP resolution were significant factors for survival.
CONCLUSION: The efficacy of empirical antibiotics, such as cefotaxime, ceftriaxone, and ciprofloxacin, against SBP was not significantly different. In addition, these antibiotics administered based on response-guided therapy were still efficacious as initial treatment for SBP, especially in those with community-acquired infections.
| Errataetall: |
CommentIn: Am J Gastroenterol. 2023 Apr 1;118(4):613-614. - PMID 36799905 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:118 |
|---|---|
| Enthalten in: |
The American journal of gastroenterology - 118(2023), 4 vom: 01. Apr., Seite 654-663 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yim, Hyung Joon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5E8K9I0O4U |
|---|
| Anmerkungen: |
Date Completed 31.03.2023 Date Revised 19.06.2023 published: Print-Electronic ClinicalTrials.gov: NCT01265173 CommentIn: Am J Gastroenterol. 2023 Apr 1;118(4):613-614. - PMID 36799905 Citation Status MEDLINE |
|---|
| doi: |
10.14309/ajg.0000000000002126 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351061215 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351061215 | ||
| 003 | DE-627 | ||
| 005 | 20231226050428.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14309/ajg.0000000000002126 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1170.xml |
| 035 | |a (DE-627)NLM351061215 | ||
| 035 | |a (NLM)36594820 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yim, Hyung Joon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis |b A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2023 | ||
| 500 | |a Date Revised 19.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT01265173 | ||
| 500 | |a CommentIn: Am J Gastroenterol. 2023 Apr 1;118(4):613-614. - PMID 36799905 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 by The American College of Gastroenterology. | ||
| 520 | |a INTRODUCTION: For the treatment of spontaneous bacterial peritonitis (SBP), cefotaxime, ceftriaxone, and ciprofloxacin were used as first-line agents. However, considering the increasing rate of antibiotic resistance, it is unclear which of these drugs can be initially recommended. This study aimed to compare the current efficacy of the 3 antibiotics, namely cefotaxime, ceftriaxone, and ciprofloxacin, for the treatment of SBP in patients with cirrhosis with ascites, when guided by therapeutic responses | ||
| 520 | |a METHODS: This study was a multicenter, prospective, randomized controlled trial. The inclusion criteria were 16- to 75-year-old patients with liver cirrhosis with ascites, having polymorphonuclear cell count of >250/mm 3 . We performed a follow-up paracentesis at 48 hours to decide continuing or changing the assigned antibiotics and then assessed the resolution rates at 120 and 168 hours of treatment | ||
| 520 | |a RESULTS: A total of 261 patients with cirrhosis who developed SBP were enrolled. Most of the patients were diagnosed as those with SBP within 48 hours of admission. The resolution rates at 120 hours, which is the primary endpoint, were 67.8%, 77.0%, and 73.6% in the cefotaxime, ceftriaxone, and ciprofloxacin groups, respectively ( P = 0.388), by intension-to-treat analysis. The 1-month mortality was similar among the groups ( P = 0.770). The model for end-stage liver disease score and the SBP resolution were significant factors for survival | ||
| 520 | |a CONCLUSION: The efficacy of empirical antibiotics, such as cefotaxime, ceftriaxone, and ciprofloxacin, against SBP was not significantly different. In addition, these antibiotics administered based on response-guided therapy were still efficacious as initial treatment for SBP, especially in those with community-acquired infections | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Cefotaxime |2 NLM | |
| 650 | 7 | |a N2GI8B1GK7 |2 NLM | |
| 650 | 7 | |a Ceftriaxone |2 NLM | |
| 650 | 7 | |a 75J73V1629 |2 NLM | |
| 650 | 7 | |a Ciprofloxacin |2 NLM | |
| 650 | 7 | |a 5E8K9I0O4U |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Kim, Tae Hyung |e verfasserin |4 aut | |
| 700 | 1 | |a Suh, Sang Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Yim, Sun Young |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Young Kul |e verfasserin |4 aut | |
| 700 | 1 | |a Seo, Yeon Seok |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Seong Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Moon Young |e verfasserin |4 aut | |
| 700 | 1 | |a Baik, Soon Koo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hong Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Young Seok |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Soo Young |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Byung Ik |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jun Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Heo, Jeong |e verfasserin |4 aut | |
| 700 | 1 | |a Sohn, Joo Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Heo, Nae-Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Kwang-Hyub |e verfasserin |4 aut | |
| 700 | 1 | |a Um, Soon Ho |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of gastroenterology |d 1953 |g 118(2023), 4 vom: 01. Apr., Seite 654-663 |w (DE-627)NLM000025445 |x 1572-0241 |7 nnns |
| 773 | 1 | 8 | |g volume:118 |g year:2023 |g number:4 |g day:01 |g month:04 |g pages:654-663 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14309/ajg.0000000000002126 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 118 |j 2023 |e 4 |b 01 |c 04 |h 654-663 | ||